Breas Medical AB Sustainability Profile
Breas Medical AB, a leading innovator in respiratory care, is headquartered in Sweden (SE) and operates extensively across Europe and beyond. Founded in 1991, the company has established itself in the medical device industry, focusing on advanced solutions for patients with respiratory conditions. Breas Medical is renowned for its cutting-edge products, including non-invasive ventilation devices and sleep therapy solutions, which are designed to enhance patient comfort and improve clinical outcomes. Their commitment to quality and innovation has positioned them as a trusted partner in the healthcare sector. With a strong market presence and a reputation for excellence, Breas Medical continues to achieve significant milestones, contributing to the advancement of respiratory care technology and improving the lives of patients worldwide.
DitchCarbon Score
How does Breas Medical AB's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Breas Medical AB's score of 57 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Breas Medical AB, headquartered in Sweden (SE), currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., which may influence its climate commitments and reporting practices. As of now, Breas Medical AB has not established any documented reduction targets or climate pledges. This lack of specific initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. Given the context of its parent company, Shanghai Fosun Pharmaceutical (Group) Co., Ltd., it is possible that Breas Medical AB's climate commitments could align with broader corporate sustainability goals set by the parent organization. However, without explicit data or targets from Breas Medical AB itself, it is challenging to provide a detailed overview of its carbon emissions and climate commitments. In summary, Breas Medical AB's current climate strategy appears to be underdeveloped, with no reported emissions data or reduction initiatives at this time.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 288,447,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 457,732,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000 | 000,000 | 0,000,000 | 000,000 | 000,000 | 00,000,000 | 00,000,000 |
How Carbon Intensive is Breas Medical AB's Industry?
How Carbon Intensive is Breas Medical AB's Location?
Breas Medical AB's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Breas Medical AB has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
